The DOI matches its Crossref record.
Survival after recurrence of Ewing Tumors: The St. Jude Children's Research Hospital Experience, 1979–1999
Open accessAbstract
BACKGROUND: Despite improved therapies, 30–40% of patients with Ewing tumors (ET) experience recurrence and have a poor prognosis. The authors analyzed factors prognostic of survival in patients with recurrent ET. METHODS: The authors assessed the relation between postrecurrence survival (PRS) and demographic, disease, and treatment factors in 71 patients who experienced recurrent ET after treatment on one of three consecutive institutional protocols. RESULTS: Thirty‐four patients (47.9%) had distant recurrence, 25 patients (35.2%) had local recurrence, and 12 patients (16.9%) had both distant and local recurrence at a median of 1.7 years after diagnosis. The probability of 5‐year PRS (± 1 standard error) was 17.7% ± 4.5%. Recurrence ≥ 2 years after diagnosis predicted a significantly better outcome (5‐year PRS, 34.9% ± 8.5%) compared with earlier recurrence (5.0% ± 2.8%; P < 0.001). Patients who had both local and distant recurrence fared worse (5‐year PRS, 12.5% ± 8.3%) compared with patients who had local recurrence alone (21.7% ± 7.8%) or distant recurrence alone (17.6 ± 6.1%). Among patients with local recurrence alone, those who underwent salvage with radical surgery had significantly higher 5‐year PRS estimates (31.4% ± 11.6%) compared with the other patients (9.1% ± 6.1%; P = 0.023). Pulmonary irradiation significantly improved the outcomes of patients with isolated pulmonary recurrence (5‐year PRS estimate, 30.3% ± 12.5% vs. 16.7% ± 10.8%, respectively; P = 0.018). CONCLUSIONS: Although outcomes are generally poor after patients experience recurrence of ET, certain patient groups differ appreciably in their likelihood of survival. Patients who experience recurrence ≥ 2 years after diagnosis and patients who have local recurrence that can be treated with radical surgery and intensive chemotherapy have the most favorable outcomes. Cancer 2002;94:561–9. © 2002 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681
Ewing's Sarcoma Family of Tumors: Current Management
Bernstein, M., Kovar, H., Paulussen, M., Randall, R. L., Schuck, A., Teot, L. A., & Juergensg, H. (2006) · The Oncologist · doi:10.1634/theoncologist.11-5-503 · Cited by 520
Risk of recurrence and survival after relapse in patients with Ewing sarcoma
Stahl, M., Ranft, A., Paulussen, M., Bölling, T., Vieth, V., Bielack, S., Görtitz, I., Braun‐Munzinger, G., Hardes, J., Jürgens, H., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23040 · Cited by 315
Murphey, M. D., Senchak, L. T., Mambalam, P. K., Logie, C. I., Klassen-Fischer, M. K., & Kransdorf, M. J. (2013) · RadioGraphics · doi:10.1148/rg.333135005 · Cited by 293
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Metadata
- Authors
- Rodriguez‐Galindo, C., Billups, C. A., Kun, L. E., Rao, B. N., Pratt, C. B., Merchant, T. E., Santana, V. M., & Pappo, A. S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-01-15
- Volume
- 94
- Issue
- 2
- Pages
- 561-569
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1991937882
- Cited by
- 166
- References
- 0
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival after recurrence of Ewing Tumors: The St. Jude Children's Research Hospital Experience, 1979–1999. https://app.cochat.ai/papers/10.1002/cncr.10192
- The paper
- Rodriguez‐Galindo, C., Billups, C. A., Kun, L. E., Rao, B. N., Pratt, C. B., Merchant, T. E., Santana, V. M., & Pappo, A. S. (2002). Survival after recurrence of Ewing Tumors: The St. Jude Children's Research Hospital Experience, 1979–1999. Cancer. https://doi.org/10.1002/cncr.10192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.